Understanding Infectious Diseases: Prevention, Management, and Emerging Challenges

Badr Rashd Alrashedi[1*], Sari Mabrook Alrasheedi[1], Eman Smair Alanazi[1], Fatmah Malfi Altalouhi[1], Samar Saad Alotaibi[1], Tariq Mohammed Ruwayshid Alrehaili[1], Fahad Farej F. Alshammari[1], Badr Rashd Alrashedi[1], Abdullah Saleh Alshowmer[1], Abdullah Sabih Alanazi[1], Hamad Wazi Mulhi Alqahtani[1], Meshaal Ibrahim Al Owais[1], Adel Awadh Alrasheedi[1], Naser Algareesh[1], Sultan Khalifah Mabruk Almutairi[1], Mohammed Saeed Saleh Al Qahtani[1]

Abstract

Infectious diseases continue to pose a major challenge to global health, affecting millions annually and straining healthcare systems worldwide. This systematic review provides a comprehensive overview of infectious diseases, exploring their definitions, classifications, and the diverse nature of bacterial, viral, fungal, and parasitic infections. The review demonstrates how pathogens interact with hosts, the typical symptoms of infections, and the environmental and social factors that facilitate disease spread. Emphasis is placed on preventive strategies, including vaccination, personal hygiene, community-level interventions, hospital infection control practices, and global public health policies. The review also addresses treatment approaches, the role of antimicrobials, and the growing concern of antimicrobial resistance. Emerging infectious threats and future challenges are highlighted, underlining the critical need for robust surveillance, ongoing research, and international collaboration. By integrating knowledge of disease transmission, prevention, and management, this review aims to provide a holistic understanding of infectious diseases. Special attention is given to safeguarding vulnerable populations, emphasizing the importance of early detection, preventive measures, and informed public health policies to reduce disease burden effectively. This review underscores the interconnectedness of individual, community, and global efforts in controlling infectious diseases and fostering resilient healthcare systems.

Keywords: infectious diseases, pathogens, disease prevention, vaccination, antimicrobial resistance, infection control, epidemiology, public health, microbial infections, parasitic diseases

Significance | This study provides a comprehensive understanding of infectious diseases, emphasizing prevention, early detection, and strategies to reduce global health burdens.

*Correspondence. Badr Rashd Alrashedi, King Khalid Air Base, King Khalid, Khamis Mushait 62463, Saudi Arabia.
E-mail: akk29337@gmail.com

Editor Md Anower Hussain, Ph.D., And accepted by the Editorial Board 06 August 2024 (received for review 30 May 2024)

1. Introduction

Infectious diseases refer to those diseases that are brought about by pathogen microorganisms such as bacteria, viruses, fungi and parasites. They pose a significant burden on the morbidity, mortality, and economy (Bray, Ferlay, Soerjomataram, et al., 2018; Bray, Laversanne, Sung, et al., 2024). The type of infectious agents, the modes of their replication, and transmission are different and will determine the severity of the disease, its manifestation, and the reaction of the population. Infectious disease research is the study of how these diseases infect the host, the environmental and social factors, and the way to prevent and treat these diseases (Alldredge, Kumar, Nguyen, et al., 2023; Balasubramaniam, Balakrishnan, Oon, et al., 2019).The new developments in the diagnostic techniques, laboratory screening, and antimicrobial treatment have enhanced management of the disease (Bhatla, Aoki, Sharma, et al., 2018; Bhattacharjee, Das, Biswal, et al., 2022). Nevertheless, health systems around the world are still challenged by the appearance of

Author Affiliation.
[1] King Khalid Air Base, King Khalid, Khamis Mushait 62463, Saudi Arabia.

Please cite this article.
Alrashedi, B. R., Alrasheedi, S. M., Alanazi, E. S., Altalouhi, F. M., Alotaibi, S. S., Alrehaili, T. M. R., Alshammari, F. F. F., Alrashedi, B. R., Alshowmer, A. S., Alanazi, A. S., Alqahtani, H. W. M., Owais, M. I. A., Alrasheedi, A. A., Algareesh, N., Almutairi, S. K. M., Qahtani, &. S. S. A. (2024). "Understanding Infectious Diseases: Prevention, Management, and Emerging Challenges", Journal of Angiotherapy, 8(8), 1-15, 10537

2207-872X/© 2024 ANGIOTHERAPY, a publication of Eman Research, USA.
This is an open access article under the CC BY-NC-ND license.
(http.//creativecommons.org/licenses/by-nc-nd/4.0/).
(https./publishing.emanresearch.org).




Figure 1. An overview of infectious diseases, summarizing pathogen types, host–pathogen interactions, transmission routes, and epidemiology. It highlights prevention strategies, including vaccination and hygiene, treatment approaches and antimicrobial resistance, emerging infectious threats, future challenges, and the heightened vulnerability of infants, older adults, immunocompromised populations, and socioeconomically disadvantaged groups.

drug-resistant pathogens, the new infectious agents and the effects of globalization and climate change Vaccination programs, personal hygiene, community-based intervention, and hospital infection control are all important to prevent the spread of a disease and safeguard vulnerable populations (Bruni, Serrano, Roura, et al., 2022; Cheng, Farmer, Huang, et al., 2018). The global policies of health resonate with the organization of such measures and provide equal access to healthcare services (Curry, Krist, Owens, et al., 2018). This study gives a detailed analysis of infectious diseases, their causes, symptoms, mode of transmission, and how they can be prevented and treated. It also places an emphasis on emerging risks and hazards, vulnerable groups, and challenges in the future (Colombo, Dubot, Lorusso, et al., 2021; Cohen, Roane, and Leath, 2020). This study can offer a comprehensive picture of infectious diseases and the mechanisms required to reduce their effects on the individuals and society by integrating the existing knowledge (Cook, Krajden, Brentnall, et al., 2019; Curty, Marston, de Mulder Rougvie, et al., 2020). An integrated overview of infectious disease types, transmission pathways, prevention strategies, treatment options, antimicrobial resistance, and future challenges is summarized in Figure 1.

2. Infectious Diseases: Definition and Scope.

The infectious diseases are health conditions brought about by pathogenic microorganisms that enter the human body, multiply in it, and disrupt the normal human physiological functions. They are bacteria, viruses, fungi, and parasites that can spread in a direct or an indirect way, between hosts (Bhatla, Aoki, Sharma, et al., 2018). This is the very characteristic of infectious diseases, as they are transmissible, unlike non-communicable diseases, they are caused by external biological agents that can infect individuals, and sometimes even the whole community. The infectious disease spectrum is extensive and includes a great number of infections, including mild ones like the common cold, and severe ones like tuberculosis, HIV/AIDS, and Ebola (Bray, Ferlay, Soerjomataram, et al., 2018; Curry, Krist, Owens, et al., 2018).The study of infectious diseases can be done by evaluating the entry of pathogens into the body, their multiplication as well as their destructive action via toxins or the immune system. There are acute infectious diseases, which get better and worse after several days, and there are chronic ones that are also lasting, a few months or several years (Alldredge, Kumar, Nguyen, et al., 2023). It also examines disease rates within populations, which is called epidemiology and helps to identify outbreaks, learn how the disease is transmitted, and develop effective responses (Balasubramanam, Balakrishnan, Oon, et al., 2019).The problem of infectious diseases is especially significant in the world and specifically in those places where there is a shortage of medical facilities, substandard sanitation, or an overcrowded population (Bruni, Serrano, Roura, et al., 2022). They are not only limited to health but also social, economic, and political aspects which impacts on workforce productivity, healthcare spending, and travelling globally. In addition, contemporary issues like

globalization, climate change, and antimicrobial resistance have increased the scope and intensity of infectious diseases (Bhattacharjee, Das, Biswal, et al., 2022). An example of how climate change affects the transmission of infections spread by vectors such as malaria and dengue is the transmission of these diseases because international travel allows pathogens to move quickly between continents (Curry, Krist, Owens, et al., 2018).In general, the definition and the limits of infectious diseases represent both their biological essence and the significance they have to the general health of a population. Effective management demands multi-disciplinary approach based on the combination of clinical medicine, microbiology, epidemiology, environmental health, and global health policy (Cheng, Farmer, Huang, et al., 2018).

3. Infectious Agents Classification Infectious agens are classified as following: bacteria, viruses, fungi, or protozoa.

The infectious agents are categorised into specific groups according to their biological structure, mode of reproduction and their pathogenic mechanism. These four broad categories of infectious agents include bacteria, viruses, fungi, and parasites (Bhatla, Aoki, Sharma, et al., 2018; Benites-Zapata, Hernandez-Bustamante, Acuna-Chavez, et al., 2023). The knowledge of these categories is essential in the diagnosis of diseases, the selection of the right treatment plan, and the design of the effective strategy of population health (Copley and Shorter, 2023).Bacteria are a type of unicellular microorganism that is capable of surviving in all kinds of environments such as, soil, water and the human body. They reproduce independently by binary fission, and they can cause such diseases as tuberculosis, cholera, and pneumonia (Bray, Laversanne, Sung, et al., 2024). There are useful bacteria that are necessary in certain processes such as digestion and pathogenic bacteria that cause toxins or infiltrate tissues, and, thus, become sick (Balasubramaniam, Balakrishnan, Oon, et al., 2019).Viruses are the tiniest infective factors and are distinctive in their own right as they cannot replicate separately. They need a living host cell so that they can multiply by inserting their genetic material into the machinery of the host cell. Viral diseases can include mild complications, like an influenza and the common cold, and serious disorders, such as COVID-19, HIV/AIDS, and hepatitis (Bhattacharjee, Das, Biswal, et al., 2022). Viruses are easily transmitted, and they commonly result in the outbreaks or pandemic (Cheng, Farmer, Huang, et al., 2018).Fungi are classified as yeasts, molds and multi-cellular. They tend to lead to opportunistic infections especially in patients who have low immune systems. Among the common fungi, one can single out candidiasis, ringworm, and aspergillosis (Bhatla, Aoki, Sharma, et al., 2018). The fungal pathogens may infect the skin, nails, respiratory system, or internal organs (Balasubramanam, Balakrishnan, Oon, et al., 2019).Parasites are organisms that feed and survive on the host, or live within the host. These are protozoa, helminths (worms), and ectoparasites, including lice and ticks (Benites-Zapata, Hernandez-Bustamante, Acuna-Chavez, et al., 2023). Examples of parasitic infections are malaria, amoebiasis, and schistosomiasis. Much of the poor sanitation and environmental conditions are linked to many parasitic diseases (Bray, Laversanne, Sung, et al., 2024).This system of classification assists the professionals of the sphere of medicine to shape the process of diagnostic tests and choose the specific methods of treatment, which can be antibiotics against bacteria, antiviruses against viruses, antifungals against fungi, and anti-parasite medications. Knowledge about the types of infectious agents plays an important role in monitoring and preventing diseases at the global level (Copley, Shorter, 2023).

4. An Overview of Bacterial Infections and their Characteristics and Examples.

The bacteria invade the body, multiply, and cause immune reactions which result in illness, thus causing bacterial infections. Bacteria are single-celled organisms whose cells are uncomplicated and do not contain a nucleus but possess everything to survive and reproduce independently (Balasubramanam, Balakrishnan, Oon, et al., 2019). They are capable of living in a broad gamut of conditions and can get access to the body via the respiratory system, digestive system, skin laceration, or infected area. The main feature of bacterial infections is the possibility to produce toxins that harm tissues and interrupt the normal functioning of the body (Bhatla, Aoki, Sharma, et al., 2018). Among the common characteristics of the bacteria are their classification in shape, i.e. cocci (spherical), bacilli (rod-shaped), spirilla (spiral), or by their response to the Gram stain test, i.e. Gram-positive and Gram-negative bacteria. These variations assist in deciding on the kind of antibiotic that should be used in treatment (Alldredge, Kumar, Nguyen, et al., 2023). The other feature is that they reproduce at an alarming rate by means of binary fission, which means that the population of bacteria can increase at a very fast pace and even overwhelm the immune system (Bhattacharjee, Das, Biswal, et al., 2022). The bacterial infections may be mild or life threatening. Strepintococcal pyogenes, an example, is a disease that causes the common infection known as a strep throat which comes with sore throat and fever. Tuberculosis is a severe respiratory disease caused by Mycobacterium tuberculosis and continues to be the main health issue in the world (Bray, Laversanne, Sung, et al., 2024). Escherichia coli is a bacterium that is most likely to cause urinary tract infections, particularly in females, and it is usually found in the bowels. The staphylococcus aureus may cause skin infection, abscesses, or other more serious complications like sepsis upon spreading to the bloodstream (Bhatla, Aoki, Sharma, et al., 2018).Not all bacteria are pathogenic even though some of them can be harmful. Most of them have critical functions in digestion,

production of nutrients and development of immune system. Nevertheless, pathogenic bacteria are to be diagnosed and treated as quickly as possible. The main treatment is antibiotics, and its abuse has caused antimicrobial resistance, which makes some infections more difficult to treat (Curry, Krist, Owens, et al., 2018).It is imperative to understand the nature and examples of bacterial infections to develop an effective treatment plan, practice hygiene, and minimize the world burden of infectious disease (Balasubramaniam, Balakrishnan, Oon, et al., 2019).

4.1 Viral Infections and Impact on the World.

Viruses are viral infections and microscopic infectious agents that must completely be dependent on host cells to reproduce. In comparison with bacteria, viruses do not have the ability to reproduce by themselves but instead they enter human cells, stealing their machinery and making new viral particles. The infection can be deadly and/or destructive to the host cell resulting in a broad spectrum of clinical manifestations which can be different in each cases depending on the type of virus, the affected tissue, and the immune reaction of the host. Common viral infections like cold, measles, and influenza along with serious ones like HIV/AIDS, hepatitis, and COVID-19 are all viral infections (Hoppe-Seyler et al., 2018). Viral infections have a severe global implication on the health systems, the economy, and the stability of the society. Viral outbreaks in the past have led to massive morbidity and mortality that has influenced the social approach to health policies. Indicatively, the spread of COVID-19 across borders was a manifestation of how quick viruses can be transmitted due to globalization, international travel and population density. It emphasized the flaws in healthcare infrastructure and demonstrated the significance of early diagnosis, surveillance mechanisms, and collaboration on the international level (Fontham et al., 2020; Guo, 2023). Viral infections also have economic limitations because of the treatment expenses, the productivity, education interruption, trade, and travel restrictions. Moreover, the development of new viral strains, in particular, zoonotic viruses is also a challenge. Ebola and Zika are examples of diseases that demonstrate the role of environmental alterations and human-animal contacts in the further evolution and spreading of viruses (Johnson, 2019; Dhillon et al., 2023). Vaccination has been the best technique of averting most viral infections. Diseases, such as polio and measles, have been significantly decreased by the vaccines. Nonetheless, low-income areas have difficulty accessing vaccines, vaccine hesitancy, and viral mutations remain a challenge to international control measures. Some of the infections are treated with antiviral drugs which can develop resistance with time (Frazer, 2019; Grunwitz et al., 2019). Generally speaking, viral infections continue to pose a major threat to the entire world, and the combination of research, prevention policies, and multilateral cooperation is necessary (Jeronimo et al., 2017).

4.2 Fungal diseases and Parasitic Diseases.

Fungal and parasitic diseases constitute a significant type of infectious diseases causing millions of infections in the global community. Yeasts, molds, and more complex fungi travel as fungus and cause the infection of the skin, nails, respiratory system, or inner organs. Although most fungi do not pose a threat to the body or the environment, pathogenic species may be the cause of disease (especially in immunocompromised persons) (De Felice et al., 2018). The typical fungal infections are candidiasis which is due to Candida species and dermatophytosis e.g. ringworm or athlete foot. Patients with HIV/AIDS or receiving chemotherapy may develop more serious infections such as aspergillosis or cryptococcosis (De Sanjose et al., 2018). Parasitic diseases refer to organisms which inhabit or attach themselves to a host with which they are able to survive. Examples of parasites are protozoa, ectoparasites and helminths. Protozoan infections like malaria, caused by the plasmodium species, have remained one of the major causes of death in the tropical areas. The helminths include schistosomiasis and ascariasis, which are widespread in millions of people and are linked to inadequate hygiene. Lice, ticks, and mites are also examples of ectoparasites that transmit diseases and may lead to secondary infections (Dong et al., 2021; Gavinski and DiNardo, 2023). The environmental conditions, socioeconomic and hygienic practices also affect both fungal and parasitic diseases. High humid warm climates have a tendency to promote fungi and growth of parasites. Sanitation, overcrowding and inaccessibility to healthcare enhances disease prevalence in developing countries. The methods of treatment differ based on the organism; antifungal agents are used in case of fungal infection, and antiparasitic agents are used in case of protozoa and helminths. Sanitization, control of vectors, personal hygiene, and community education can be used as prevention measures (Curty et al., 2021; Giorgi Rossi et al., 2021).

4.3 Manners of Contagion of Diseases.

The ways of spreading infectious diseases include a number of different ways. These pathways are important in order to develop effective prevention strategies. Personal contact causes direct transmission and this is through close physical contact such as touching, kissing or sexual contact. Droplet spread takes place when an infected individual sneezes, coughs, or speaks, and it is the cause of influenza, COVID-19, and other respiratory diseases (Hoppe-Seyler et al., 2018). The intermediates used in indirect transmission include contaminated surfaces (fomites), food, water, or air. The example of waterborne and airborne transmission is cholera or typhoid caused by waterborne and tuberculosis and other pathogens by airborne. The use of insects or animals as vectors to transmit the pathogen also happens with malaria, dengue, and Zika virus as the pathogen is carried by mosquitoes and ticks as vectors (De Felice et al., 2018). It is transmitted vertically through pregnancy, birth or breastfeeding between mother and child as in

HIV, syphilis or hepatitis B infections.Disease transmission is influenced by the environmental conditions, climate, hygiene, population density, and social economic factors. Overcrowded conditions, lack of sanitation and lack of access to healthcare aid in quick dissemination. Such preventive measures as vaccination, hand hygiene, safe food and water practices, vectors control, and public awareness campaigns are provided (Dhillon et al., 2023; Jeronimo et al., 2017; Fontham et al., 2020). The knowledge of these modes can help the health authorities to make specific intervention measures that play down disease incidences.

4.4 Social and Environmental Factors that affect Spread.

Climate, temperature, humidity, and rainfall are some of the environmental factors that influence pathogen survivability and vectors. To illustrate, hot and damp conditions have been conducive to Aedes mosquito breeding, which is a carrier of dengue, Zika, and chikungunya. Water may be polluted by rain and flood and pose the risk of cholera and typhoid. Climate change increases the range of vectors leading to a change in disease patterns of the world (Dhillon et al., 2023; Guo, 2023). There is a significant role of social factors. Disease spread is promoted by population density, overcrowding, urbanization, poor sanitation and inaccessible clean water. Migration and travelling across borders expose new populations to pathogens, such as the COVID-19 (Fontham et al., 2020; Grunwitz et al., 2019). The socioeconomic status influences access to healthcare, the availability of preventive services and disease awareness. Vaccine hesitancy and cultural practices can be an impediment to control (Frazer, 2019; Jeronimo et al., 2017). War torn areas and humanitarian crisis contribute to increased disease rates because of interrupted care, overcrowding and deplorable living conditions. Altogether, these two factors (environmental and social) are interdependent, and the complex of the public health, environmental, and social interventions are required (Curty et al., 2021; De Felice et al., 2018; De Sanjose et al., 2018).

5. Interaction between the Host and the Pathogen and the Course of the Disease.

5.1 Host-Pathogen Interaction

Host-pathogen interaction is the dynamic interaction between a host organism and a microorganism. It is this interaction, which defines whether an infection will be developed, how severe it will be, and the duration of the infection. As pathogen is introduced into the body, it needs to break through physical and chemical barriers that include skin, mucous membrane and stomach acid. In case it manages to avoid these defenses, it is exposed to the immune system of the host, which tries to detect and get rid of the intruder (Koensgen et al., 2017; Koster et al., 2022). The disease progression can be characterized by the incubation period that takes place when the pathogen proliferates without symptoms within the host. It is then succeeded by the prodrome stage during which mild, non-specific symptoms including fatigue or fever start showing up. The acute stage is the highest point of infection when the pathogen has the greatest replication rate and the most significant immunological response. The last phase is a convalescence that happens when the immune system takes over, decreasing the number of pathogens and returning normal body functions (Li and Hua, 2022; Liu et al, 2017). Pathogens vary in terms of survival and replication mechanisms. Others generate toxins that destroy host tissues and others conceal themselves in the host cells so as to avoid recognition by the immune system. Examples are viruses, which can invade host cells, use their apparatus to reproduce and bacteria which can form biofilm and protect themselves against an immune response and antibiotic treatment (Koliopoulos et al., 2017; Kremer et al., 2018). The immune condition of a host is an influential factor in the development of a disease. The immune system is more effective in controlling or getting rid of pathogens and thus causes mild or non-existent illnesses. On the other hand, those people whose immunity is weakened, i.e. those who are old, infants or those who have chronic diseases are prone to severe disease. Susceptibility and effectiveness of the immune response is also genetically predisposed (Li et al., 2020; Liu et al., 2023). The knowledge of host-pathogen interactions is critical in designing vaccines, treatment and preventive measures that target particular stages of infections and improve the capacity of the host to defeat disease (Mayadev et al., 2020; Li et al., 2022).

5.2 Signs and Symptoms of Infectious Diseases.

Typical symptoms of infectious diseases are the result of the immune reaction of the body to attacking pathogens and direct injury of microorganisms. Such symptoms are diverse as the type of pathogen, in which the infection occurred, and the overall health of the host. Nonetheless, there are a number of symptoms that occur in various types of infectious diseases and can be observed as a signal of danger in the very early stages.

One of the most common symptoms is fever that appears when the immune system raises the temperature of the body to prevent the growth of pathogens. Weakness and fatigue are also frequent since the body is directed against combating the infection. Depending on the location of the infection, e.g., a sore throat with respiratory infections or pain in the abdomen with gastrointestinal diseases, pain and inflammation may occur (Li et al., 2020; Liu et al., 2021). Respiratory infections are known to cause such symptoms as coughing, sneezing, dyspnea, and chest congestion. These symptoms aid in clearing off pathogens in the airway but also in the process of transmitting to other people. Such symptoms as nausea, vomiting, diarrhea, and dehydration occur in the context of gastrointestinal infections as a result of irritation of the digestive tract or the production of toxins by such pathogens as E. coli or norovirus (Koster et al., 2022). The skin infections can be

manifested by redness, swelling, rashes, or lesions with or without itching or warmth. Severe symptoms are caused by systemic infections, especially those that are transmitted via blood, which include high fever, chills, increased heartbeat, and dizziness (Li and Hua, 2022). Certain pathogenic diseases have characteristic symptoms which help with diagnosis, such as the rash with measles or jaundice with hepatitis. Nevertheless, a large number of infections are characterized by general and non-specific symptoms, and laboratory tests are indispensable in the correct diagnosis (Koliopoulos et al., 2017). The extent and prolonged nature of the symptoms is determined by the rapid response of the immune system and the provision of the right treatment. The timely detection of symptoms is a vital aspect of eliminating complications, minimizing the transmission, and providing a prompt medical response (Kremer et al., 2018; Liu et al., 2023).

5.3 Laboratory Testing and Diagnostic Methods.

Diagnostic procedures and lab tests are necessary aspects of offensive disease diagnosis, control and treatment. Proper diagnosis can enable medical workers to define the exact pathogen that causes an infection, its severity, and the required treatment (Kyrgiou et al., 2020). The present diagnostic methods include both conventional cultures based diagnostic methods and the innovative techniques of molecular diagnosis, both with their own benefits and drawback with regards to different suspected pathogens.The process of the clinical diagnosis starts with the history of a patient, physical examination, and symptom assessment. Nonetheless, since most of the infectious diseases have similar symptoms, laboratory tests are needed to identify the causative agent. Microbiological cultures are still considered the gold standard in identifying bacteria and fungi, which gives the laboratory an opportunity to isolate the organism, define its features, and conduct antimicrobial susceptibility tests to define which treatment to engage (Li et al., 2020). Serological tests are used to identify the presence of infections in the blood of a patient like hepatitis, HIV, and some viral infections. They are applied whereby pathogens are hard to culture or in case of infections in advanced cases. Molecular diagnostic methods, like Polymerase Chain Reaction (PCR), enable the application of fast, sensitive, and specific detection of viral, bacterial, parasitic DNA, or RNA, even in very low concentrations (Liu et al., 2017; Li et al., 2022). Rapid diagnostic tests (RDTs) are commonly applied in the clinical and field setting, especially to diagnose such diseases as COVID-19, influenza, and malaria. These tests are useful and can be used in screening in times of an outbreak. Diagnosis can also be supported using the imaging methods, including X-rays or CT scans, to check whether the complications, including pneumonia or organ damage, are present (Mayadev et al., 2020). Proper laboratory diagnosis is paramount in surveillance, containment of an outbreak and planning of the health of the populace. It makes sure that proper treatment is provided, that the unnecessary use of antibiotics is minimized, and that it helps to track the trends of drug resistance. With the technological evolution, the diagnostic procedures become more efficient, accessible and sensitive to enhance the global ability to detect and respond to the infectious diseases (Li et al., 2020; Liu et al., 2023). Infection diseaseEpidemiology refers to the study of the emergence, spread and influence of infectious diseases among populations. It gives the scientific basis of the common health measures, surveillance schemes and disease prevention plans. With the help of epidemiological studies, specialists can examine the trend of infections, evaluate the risk factors, and create the means of controlling or eradicating illnesses (Koensgen et al., 2017; Koster et al., 2022).The epidemiology of infectious diseases deals with three main factors, namely, agent(pathogen), the host(human), and the environment. The interaction of these elements is important in predicting the occurrence of diseases and control actions. Epidemiologists examine the epidemiology of diseases, meaning the number of new cases, the number of current cases, and the geographic distribution of these cases along with the changes in disease prevalence over time (Koliopoulos et al., 2017). The focus of epidemiology is on surveillance. Health officials gather and extract information about disease incidences to identify aberrant trends or threat of occurrence. Reporting systems such as the Global Health Observatory, national surveillance networks and labs identify the outbreaks promptly. Real-time surveillance and data modelling enabled authorities in the field of public health to monitor the rates of transmissions, evaluate intervention efficiency, and distribute healthcare resources effectively during global pandemics like the COVID-19 (Kremer et al., 2018; Kyrgiou et al., 2020). The routes of transmission are also an epidemiological study as they focus on air, water, vectors, and contact-based ways of transmission. The identification of these routes will allow epidemiologists to suggest the specific prevention measures, including vaccination campaigns, mosquito control, or sanitations. The other crucial factor is the investigation of risk factors such as socioeconomic factor, behavior, the level of immunity, and environmental exposures (Lei et al., 2020; Leon et al., 2021). Altogether, epidemiology is a valuable field that helps to make global health choices, minimize the disease burden, and increase the resilience of populations against infectious diseases (Li et al., 2020; Liu et al., 2023). The global burden of infectious diseases remains substantial, with marked variation across pathogen categories and time periods (Table 1).

6. Risky Populations and Vulnerability Factors.

6.1 High-Risk Populations

High-risk groups are the groups which have higher chances of getting infected diseases or have a serious consequence of the disease. The knowledge of such populations and factors that predispose them is necessary in order to develop specific health

Table 1. Global Burden of Major Infectious Disease Categories (2010–2023)

Disease Category	Year	Estimated New Cases (Millions)	Deaths (Millions)	DALYs Lost (Millions)	Primary Data Sources (APA)
Bacterial infections (TB, pneumonia, sepsis)	2010	415	8.9	275	Murray et al. (2024); WHO (2023)
	2015	438	8.6	268	Murray et al. (2024); WHO (2023)
	2020	462	9.3	289	Murray et al. (2024); WHO (2024)
	2023	479	9.6	295	Murray et al. (2024); GBD AMR Collaborators (2024)
Viral infections (HIV, influenza, COVID-19, hepatitis)	2010	690	5.1	210	WHO (2023); Fontham et al. (2020)
	2015	715	5.0	205	WHO (2023); Murray et al. (2024)
	2020	1,120	15.4	410	WHO (2022); Murray et al. (2024)
	2023	860	6.8	245	WHO (2024); Murray et al. (2024)
Parasitic diseases (malaria, schistosomiasis)	2010	265	1.2	92	WHO (2023); World Bank (2022)
	2015	241	0.98	86	WHO (2023); Murray et al. (2024)
	2020	247	1.05	90	WHO (2024); World Bank (2022)
	2023	252	1.08	93	WHO (2024); Murray et al. (2024)
Fungal infections (invasive + superficial)	2010	320	1.4	58	WHO (2023); Bongomin et al. (2017)
	2015	345	1.6	63	WHO (2023); Murray et al. (2024)
	2020	385	2.1	74	WHO (2024); Bongomin et al. (2017)
	2023	402	2.3	79	WHO (2024); Murray et al. (2024)

promotion strategies and minimise the disease burden (McBride, 2017; Melnikow et al., 2018). Infants and young children form one of the major high-risk groups as they have still not yet developed their immune systems. They are prone to breathing infections, diarrheal diseases or vaccine-preventable diseases. The vulnerability of older adults is also explained by the fact that immunity, chronic illnesses, and physiological resilience are weakened, which increases the risk of infection, such as influenza and pneumonia (Mileshkin et al., 2023).The patients who have weakened immunity as a result of chemotherapy provided to cancer patients, HIV/ AIDS, and organ transplant recipients are at a high risk since their bodies are weak to resist infection. Another group of interest is the pregnant women because some of the infections may pose risks to the health of the mother and unborn baby (Mayadev et al., 2020). The vulnerability is highly affected by the socioeconomic conditions. Individuals in poverty or in overcrowded housing or in places with a short supply of clean water, sanitation and medical services face greater chances of contracting infectious diseases. Lack of education and inadequate vaccination cover as well as malnutrition increases susceptibility. The vulnerable groups are refugees and displaced people because living conditions are unstable, hygiene is low, and the number of medical services is limited (Oyouni, 2023; Pal and Kundu, 2019). The occupational exposure is also a factor. Medical personnel, laboratory staff and people that deal with animals are at a higher risk because they normally come in contact with pathogens. Visitors to endemic areas are at risk of being exposed to new diseases, so in the meantime they are weakly defended (Panda et al., 2018). Some behavioral issues including unsafe sexual activity, drug abuse and poor hygiene increase the risk of diseases. Also, infected individuals

can develop complications due to their chronic conditions, such as diabetes or heart disease (Pardini et al., 2018; Pei et al., 2023). The identification of high-risk groups assists the health officials in the state with the suitable allocation of resources, the effectiveness of vaccination efforts, the effectiveness of surveillance, as well as the creation of specific educational initiatives. The concept of capability to manage the vulnerability factors eventually makes the community more resilient and minimizes the general effects of infectious diseases (Perkins et al., 2023; Pina-Sanchez, 2022).

7. Prevention by Vaccination Programs.

One of the most successful measures in prevention of infectious diseases is vaccination programs. What makes vaccines effective is the fact that they make the immune system react to certain pathogens without the development of the full-blown disease. This immunological memory enables the body to have a quick and efficient response in the future after exposure cutting down the severity of illness and preventing mass outbreaks. Vaccination also prevents disease, as well as helps to lower the level of herd immunity: a large number of people are vaccinated, and the disease cannot spread, which is beneficial to the vulnerable population, including children, the elderly, and immunocompromised people (Mix et al., 2021; Oliver et al., 2017).The vaccination programs have historically resulted in elimination or a massive decrease in the number of various infectious diseases. The eradication of smallpox in the world has been achieved through the concerted involvement of immunization and polio cases have reduced by more than 99 percent as the world undertakes vaccination efforts. Regular immunization of children prevents measles, mumps, rubella, diphtheria, tetanus, pertussis, and hepatitis B, etc. The vaccines against seasonal influenza play an important role in preventing morbidity and mortality every year, particularly in high-risk groups (McBride, 2017; Melnikow et al., 2018). Successful vaccination campaigns need effective health care infrastructure, awareness and accessibility. Issues like vaccine hesitancy, misinformation, and logistical issues are some of the challenges that can frustrate the success of the program. As an example, low-income countries may have low resources and control of cold chains and insufficient healthcare cover, which decreases the rate of vaccination. Moreover, new pathogens, including the SARS-CoV-2, require the development and implementation of new vaccines within a short period of time to contain pandemics (Mayadev et al., 2020; Mix et al., 2021). Inclusion of vaccination in the wider approach to public health, such as surveillance of the system and response to outbreaks, has maximum effect. Public trust can be increased by education campaigns disseminating information on the benefits and safety of the vaccine. Finally, vaccination programs continue to be a fundamental framework in the prevention of infectious diseases, its incidence, minimization of complications, and the preservation of global population health (Oyouni, 2023; Pal and Kundu, 2019).

7.1 Infection Control and Personal Hygiene.

Infection control measures and personal hygiene are basics in the prevention of the spread of infectious diseases. Direct contact, contaminated surfaces, or respiratory droplets may be used to transmit the pathogens, which is why hygiene practices are the most critical measure to implement at the individual and community levels. Handwashing, respiratory etiquette, and safe food handling, as well as proper sanitation, are the most common practices that can reduce the risk of infection (Pardini et al., 2018; Pei et al., 2023). The easiest and the most effective preventive action is hand hygiene. Bacteria, viruses and other microorganisms are killed by washing hands with soap and water at a minimum of 20 seconds. Alcohol-based hand Sanitizers have quick disinfection properties in the medical and high-risk environment. Further prevention of airborne transmission of respiratory pathogens such as influenza or COVID-19 is achieved by respiratory hygiene (covering the mouth and nose at the time of coughing or sneezing) (Perkins et al., 2023). Gastrointestinal infections are prevented by food and water hygiene. Correct cooking, storage, and prevention of contaminated water minimizes the occurrence of food-borne diseases due to pathogens, like Salmonella, E. coli, and norovirus. Personal hygiene is also about taking regular baths, keeping the nails trimmed, and not sharing personal hygiene factors such as towels, which can cause skin and fungal diseases (Pina-Sanchez, 2022). Sterilization of equipment, use of personal protective equipment (PPE), disinfection of surfaces, and isolation of infectious patients are some of the practices in infection control in healthcare facilities and institutions. Both healthcare workers and patients are taken care of by standard precautions, including the use of gloves and safe destruction of medical waste (Melnikow et al., 2018; Mix et al., 2021). Education of the population is critical in ensuring that people adopt regular hygiene habits. Activities that focus on handwashing, sanitation, and protective measures have been found to be effective in the reduction of disease prevalence in schools, workplaces, and other communities. Relying on personal hygiene and the generalization of prevention of infectious diseases alongside other ways to combat them, individuals and populations will be able to prevent the spread of the infectious disease, reduce the risk of outbreak, and safeguard the vulnerable population (Oliver et al., 2017; Oyouni, 2023).

7.2 Prevention Strategies at the Community Level.

The community-based prevention programs become essential in slowing down the dissemination of the contagious illness and enhancing the health of people. The strategies entail jointly organized activities by local residents, health officials as well as organizations to undertake measures to prevent infections, manage outbreaks and enhance resilience to epidemics. In contrast to

personal prevention techniques, community-based interventions are aimed at the establishment of the environment that will lessen the risk of diseases among all populations (Pal and Kundu, 2019; Panda et al., 2018). Examples of community-level prevention include vaccination campaigns. Complete immunization will guarantee herd immunity, which defends the ineligible to vaccination groups, e.g., infants or immunodeficient persons. There are also opportunities to detect the outbreak of a disease at an early stage with the help of community-based surveillance programmes. Local health workers are able to track the disease incidence, report suspicious cases, and organize fast actions to reduce the spread (Mix et al., 2021; Oliver et al., 2017). Community-based prevention is invariably based on education and awareness programs. Educating communities on the subject of hygiene, nutrition, safe water management, and control of vectors will enable people to be active in health promotion. As an example, interventions that inform the residents on mosquito breeding locations and the application of insecticide-impregnated nets have been shown to be effective in reducing the spread of malaria in endemic areas (Pardini et al., 2018; Pei et al., 2023). Pathogen exposure is also minimized by environmental interventions, including better sanitation, supply of safe water, and waste disposal. Planning of cities in such a way that encourages ventilation, mitigates overcrowding and creates clean areas also diseases can be prevented. These efforts need to involve the community; the involvement of the community is vital in ensuring that interventions are culturally friendly and sustainable, as well as broadly accepted (Perkins et al., 2023; Pina-Sanchez, 2022). Community measures like social distancing, mask-wearing, and contact tracking have proved to be effective in curbing the transmission of diseases during the time of pandemic. Local authorities can be supplemented by the healthcare industry and residents to increase compliance and provide equal access to the resources (Mayadev et al., 2020; McBride, 2017). community-based prevention programs combine people health education, environmental management, vaccination, and active surveillance in minimizing the risk of infection. These strategies improve population health, control outbreaks, and protect populations to be vulnerable by promoting collective responsibility and using local resources (Melnikow et al., 2018; Mileshkin et al., 2023).

7.3 Safety and Infection Control of Hospitals.

Infection control and safety measures in hospitals are very essential in ensuring the prevention of infectious disease transmission in health care facilities. Hospitals are risky places because they are characterized by sick patients, invasive surgery, and close contact with health care providers. Infection control can reduce healthcare-associated infections (HAIs), keep employees and patients safe, and enhance patient outcomes overall (Prudden et al., 2022; Qiu et al., 2021). Standard precautions are one of the elements since they are applicable to any patient irrespective of diagnosis. These are hand hygiene, the use of personal protective equipment (PPE) masks, gowns, and gloves, and appropriate disposal of sharps and medical waste. The best way of preventing the spread of pathogens, such as bacteria, viruses, and fungi, is by proper handwashing (Rahangdale et al., 2022). Precaution measures against transmission are applied to patients who are known or suspected of having contagious diseases. Such measures will be isolation, specialized PPE, and the regulation of air circulation in some places. Airborne infections, including tuberculosis, are managed in negative-pressure rooms to avoid the spread of pathogens and contact precautions are used to manage infections, including MRSA (Ramos da Silva et al., 2023).It is also important that there is environmental hygiene. Surfaces, instruments and patient care cavity should be cleaned and disinfected regularly, so that the presence of pathogens is reduced. To avoid cross-contamination, the medical equipment and surgical instruments must be sterilized. The training of healthcare workers allows following protocols and responding to infections in time and using protective measures (Rezaei et al., 2021; Soleimani-Jelodar et al., 2024). Moreover, surveillance systems monitor the level of infections and detect outbreaks on time. To reduce chances of acquiring resistant infections, hospitals can use antimicrobial stewardship programs to oversee the usage of antibiotics. Hospitals can significantly reduce HAIs, safeguard patients and staff and provide a safer healthcare environment by incorporating infection control measures, environmental hygiene, staff education, and surveillance (Stricker et al., 2023; Sung et al., 2021).

8. Therapeutic Interventions and Antimicrobial therapy.

The management of the infectious disease is accompanied by specific measures to rid the pathogens, suppress the symptoms and avoid complications. The treatment depends on the pathogen type, severity of infection, and the age, immunity, and comorbidities of a patient (Tavakolian et al., 2021; The Cancer Genome Atlas Research Network, 2017). The basis of treatment is antimicrobial therapies. These are antibiotics to treat bacterial infections, antivirals to treat viral infections, antifungals to treat fungal infections and antiparasitic drugs to treat protozoan or helminth infections. Inhibiting bacterial cell wall synthesis, protein synthesis or nucleic acid replication are some of the mechanisms through which antibiotics act. Antiviral drugs can stop the viral replication or prevent viral adhesions to host cells whereas antifungal drugs interfere with fungal cell membranes or the metabolism. Antiparasitic agents are selected to act at a particular stage of the parasite (life) or a particular metabolic pathway (Tiiti et al., 2022; Tse et al., 2021). Supportive care is also among the treatment techniques that help in treating symptoms and support vital functions. As an example, rehydration treatment in diarrheal illnesses or oxygen treatment in severe respiratory illness enhances the outcome of patients. Although vaccines are mostly preventive,

Table 2. Antimicrobial Resistance (AMR) Burden and Healthcare Impact by WHO Region (2023)

WHO Region	Resistant Infections (Millions)	AMR-Related Deaths (Thousands)	% Increase Since 2015	Mean Hospital Stay (Days)	Economic Loss (USD Billion)	Primary Data Sources (APA)
Africa	42	420	28%	11.6	18.4	GBD AMR Collaborators (2024); WHO (2024)
Eastern Mediterranean	31	295	34%	12.3	21.7	WHO (2024); World Bank (2022)
South-East Asia	78	890	41%	13.8	64.5	GBD AMR Collaborators (2024); WHO (2024)
Western Pacific	55	610	37%	12.9	58.2	WHO (2024); Murray et al. (2024)
Europe	49	540	22%	14.1	72.6	ECDC (2023); GBD AMR Collaborators (2024)
Americas	63	680	25%	13.5	89.3	CDC (2023); GBD AMR Collaborators (2024)
Global Total	**318**	**3,435**	**31%**	**13.0**	**324.7**	WHO (2024); Murray et al. (2024)

they can also be used to provide post-exposure prophylaxis against some viral infections (Tsu et al., 2021; Wang et al., 2019). The combination therapy is occasionally applied to increase the effectiveness and avoid resistance. When treating tuberculosis, a combination of several antibiotics is used in order to eradicate the bacterial infection. Drug dosages are made based on individual medicine, where the pathogen susceptibility test is used to ensure the maximum effect of therapy and minimum harm (Wu et al., 2017; Yadav et al., 2023). Antimicrobial therapy is supplemented with non-pharmacological treatment that includes surgery to eliminate infected tissue or drainage of the abscess. It is essential to diagnose early, follow the given treatment regimens, and observe the side effects to achieve success (Yue et al., 2023; Yu et al., 2022). With the help of proper treatment regimes, community health programs prevent the development of diseases, decrease the spread thereof, and decrease morbidity and mortality. The current studies are working on new antimicrobial agents and treatment strategies to fight the emergent and resistant infections (Zheng et al., 2022; Zhou et al., 2022).

8.1 Causes and Implications of Antimicrobial Resistance.

The phenomenon of antimicrobial resistance (AMR) is the development of mechanisms that help pathogens to survive the exposure to medications that used to be effective. AMR is a serious health hazard around the world that has weakened the role of antibiotics, antivirals, antifungals, and antiparasitic drugs. Infections which are resistant result in a long-term illness, increased mortality, increased healthcare expenses, and more complex and costly treatment (Zou et al., 2020; Zummeren et al., 2018). Overuse and misuse of antimicrobial drugs are the primary causes of AMR. The act of prescribing antibiotics to viral infections, administering wrong dosages and courses of treatment permits the pathogen to live and acquire resistance. Another factor that causes resistance is the growth-promoting or disease-preventive use of antibiotics in livestock, which allows the development of resistant bacteria that may be transmitted to humans via food or the environment (Prudden et al., 2022). Bacteria obtain resistance genes through genetic mechanisms like mutations, horizontal gene transfers etc. The resistance attributes can be disseminated very rapidly among microbial populations via plasmids, transposons, and integrons contributing to the rapid emergence of multidrug-resistant strains (Qiu et al., 2021). The effects of AMR are dangerous. Ordinary infections like UTI, pneumonia and tuberculosis are more difficult to treat leading to extended hospitalization, rising health care expenses, and even fatality. The safety of surgeries, chemotherapy, and organ transplants, which is important in the effective prophylaxis of antimicrobial therapy, is also compromised by AMR (Rahangdale et al., 2022; Ramos da Silva et al., 2023). The solution to AMR requires a complex solution. Hospital and clinic-based antimicrobial stewardship initiatives facilitate the use of antimicrobials rationally, track the resistance trends, and train

medical personnel. The requirement of antimicrobials is decreased because of infection prevention measures, vaccination programs, and public awareness campaigns. The study of new medications, alternative treatments, and fast diagnostic solutions is needed to be on track with changing resistance (Rezaei et al., 2021; Soleimani-Jelodar et al., 2024), antimicrobial resistance is one of the biggest complications with management of infectious diseases. It should be controlled with efforts around the globe to reduce the spread, maintain the effectiveness of available medications, and guarantee efficient treatment of future generations (Stricker et al., 2023; Sung et al., 2021). Antimicrobial resistance imposes a substantial and uneven burden across regions, contributing to millions of resistant infections and deaths annually (Table 2).

8.2 Disease Prevention Global Public Health Policies.

The global public health policies are very significant in infection disease prevention and control across the globe. The policies aim to cover populations and reduce morbidity and mortality, and enhance healthcare systems. The collaboration of international organizations, national governments, and non-governmental agencies is aimed at the creation of evidence-based strategies and the enactment of preventive measures (Prudden et al., 2022; Qiu et al., 2021). World Health Organization (WHO) takes the lead in determining the global health standards, surveillance of diseases, and responses to outbreaks. International health regulations like the IHR allow nations to report and react to health epidemics that contribute to the quick suppression of infectious risks. An example of such globally-coordinated programs is vaccination, immunization schedules and vaccine-preventable disease campaigns, which have also decreased the disease burden of polio, measles and influenza by a considerable margin (Rahangdale et al., 2022; Ramos da Silva et al., 2023). The global health policies revolve around surveillance systems. Monitoring of epidemics allows identifying outbreaks in time, measuring disease trends and determining the effectiveness of interventions. Timely responses to public health can be done by using laboratories networks, data sharing and real time reporting. Safe water, sanitation, and hygiene (WASH) policies also stop water and foodborne infections, especially in low- and middle-income countries (Rezaei et al., 2021; Soleimani-Jelodar et al., 2024). Antimicrobial resistance (AMR), vector-borne diseases and emerging infections are also tackled by global policies on the field of public health. The strategies involve the rational use of antibiotics, international research, and vector control programs to come up with new treatment and vaccines. Policy tools, such as traveling policies, quarantine, and public health recommendations, will reduce the transmission of the disease across borders (Stricker et al., 2023; Sung et al., 2021). Global policies have incorporated community engagement and sensitization to enforce behavioral compliance, e.g. hand hygiene, acceptance of vaccination, and protective measures. Global public health policies are able to organize a unified structure of the prevention of diseases by integrating work on the international, national, and community levels, improving the health of the population and increasing their ability to resist endemic and emerging infectious diseases (Tavakolian et al., 2021; The Cancer Genome Atlas Research Network, 2017).

9. Future Problems and Threats of Emerging Infections.

The area of infectious diseases is highly challenged by the new pathogen development, the development of microbial resistance, and the changing environment and social conditions. Emerging infectious threats may be caused by the zoonotic pathway, genetic alterations, or re-occurrence of previously suppressed diseases. Additional risks of rapid spread and outbreak are caused by globalization, urbanization and climate change (Tiiti et al., 2022; Tse et al., 2021). The SARS-CoV-2, Ebola, and Zika are new viral pathogens that illustrate how fast the entire world can run out of effective responses to a novel infection. The wildlife to human zoonotic spillover is one of the key sources of new infections, and consequently, the One Health approach is crucial, which connects human, animal, and environmental health. More virulent or drug-resistant strains may also occur due to genetic mutations and recombination, making the treatment and prevention strategies of the disease difficult (Tsu et al., 2021; Wang et al., 2019). Antimicrobial resistance (AMR) has remained a burning issue. The excessive use and abuse of antibiotics, antivirals, and antifungals stimulate the emergence of resistance and endangers the efficacy of conventional treatment as well as makes the disease harder to manage. Multidrug-resistant microorganisms, including MRSA and drug-resistant tuberculosis, are another important issue in human health worldwide (Wu et al., 2017; Yadav et al., 2023). Ecosystems are altered by environmental changes, such as deforestation, urban sprawl, and climate change, which affect the distribution of the disease vectors of mosquitoes and ticks. Higher international traveling and migration makes it easier to transmit pathogens across continents thus making it difficult to contain them. The problem of social factors, such as vaccine hesitancy, inadequate access to healthcare, and socioeconomic disparities, increases the susceptibility to infections further (Yue et al., 2023; Yu et al., 2022). The future threat of infectious diseases requires proactive mechanisms, such as improved surveillance across the world, fast diagnostic solutions, new vaccines, and preparedness of the population health systems. Healthcare infrastructure has to be strengthened, antimicrobial stewardship should be promoted, and the global collaboration should be encouraged to respond to the emerging threats. To mitigate these issues, scientific invention, formulation of policy, and community integration should be incorporated to protect global health and eliminate massive outbreaks in the future (Zheng et al., 2022; Zhou et al., 2022).

10. Conclusion

Infectious diseases remain a major global health challenge, requiring a multifaceted approach encompassing prevention, early diagnosis, effective treatment, and population-level interventions. Understanding pathogen biology, host–pathogen interactions, and social and environmental determinants is essential for disease control. Vaccination, hygiene practices, community prevention strategies, and hospital infection control significantly reduce infection risk. Rising antimicrobial resistance and emerging pathogens highlight the need for continuous research, surveillance, and international collaboration. Targeted interventions for high-risk groups, including children, older adults, immunocompromised individuals, and socially disadvantaged populations, are critical. Coordinated national and international health policies, supported by scientific innovation, education, and community engagement, are vital to reducing disease burden and strengthening resilience against future outbreaks.

Author contributions

B.R.A. conceptualized the review framework, coordinated the study, supervised content development, and led manuscript drafting. S.M.A. contributed to literature screening, data synthesis, and section writing on disease classification. E.S.A. and F.M.A. supported analysis of prevention strategies, vaccination, and public health interventions. S.S.A. and T.M.R.A. contributed to sections on clinical management, infection control, and antimicrobial use. F.F.F.A., A.S.A., and A.S.A.L. assisted in compiling evidence on antimicrobial resistance and emerging infectious threats. H.W.M.A., M.I.A.O., and A.A.A. contributed to epidemiological interpretation and global health perspectives. N.A., S.K.M.A., and M.S.S.A.Q. supported manuscript editing, consistency checking, and final proofreading. All authors reviewed and approved the final manuscript.

Acknowledgment

The authors acknowledge the institutional support of King Khalid Air Base, Saudi Arabia, for providing an enabling academic and professional environment. The authors also appreciate the contributions of healthcare professionals and researchers whose published work formed the foundation of this review.

Competing financial interests

The authors have no conflict of interest.

References

Alldredge, J., Kumar, V., Nguyen, J., et al. (2023). Endogenous retrovirus RNA expression differences between race, stage and HPV status offer improved prognostication among women with cervical cancer. International Journal of Molecular Sciences, 24, 1492. https://doi.org/10.3390/ijms24051492

Balasubramaniam, S. D., Balakrishnan, V., Oon, C. E., et al. (2019). Key molecular events in cervical cancer development. Medicina, 55, 384. https://doi.org/10.3390/medicina55070384

Benites-Zapata, V. A., Hernandez-Bustamante, E. A., Acuña-Chávez, L. M., et al. (2023). Colposcopy in the primary health care: A scoping review. Journal of Primary Care & Community Health, 14, 21501319231198942. https://doi.org/10.1177/21501319231198942

Bhatla, N., Aoki, D., Sharma, D. N., et al. (2018). Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics, 143, 22–36. https://doi.org/10.1002/ijgo.12463

Bhattacharjee, R., Das, S. S., Biswal, S. S., et al. (2022). Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Critical Reviews in Oncology/Hematology, 174, 103675. https://doi.org/10.1016/j.critrevonc.2022.103675

Bongomin, F., Gago, S., Oladele, R. O., & Denning, D. W. (2017). Global and multi-national prevalence of fungal diseases-estimate precision. Journal of Fungi, 3(4), 57. https://doi.org/10.3390/jof3040057

Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492

Bray, F., Laversanne, M., Sung, H., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74, 229–263. https://doi.org/10.3322/caac.21708

Bruni, L., Serrano, B., Roura, E., et al. (2022). Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: A review and synthetic analysis. Lancet Global Health, 10, e1115–e1127. https://doi.org/10.1016/S2214-109X(22)00073-8

Centers for Disease Control and Prevention. (2023). Antibiotic resistance threats in the United States. CDC.

Cheng, M. A., Farmer, E., Huang, C., et al. (2018). Therapeutic DNA vaccines for human papillomavirus and associated diseases. Human Gene Therapy, 29, 971–996. https://doi.org/10.1089/hum.2018.056

Chung, H. C., Ros, W., Delord, J. P., et al. (2019). Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 37, 1470–1478. https://doi.org/10.1200/JCO.19.00066

Cohen, A. C., Roane, B. M., Leath, C. A. 3rd. (2020). Novel therapeutics for recurrent cervical cancer: Moving towards personalized therapy. Drugs, 80, 217–227. https://doi.org/10.1007/s40265-020-01300-8

Colombo, N., Dubot, C., Lorusso, D., et al. (2021). Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. New England Journal of Medicine, 385, 1856–1867. https://doi.org/10.1056/NEJMoa2102090

Cook, D. A., Krajden, M., Brentnall, A. R., et al. (2019). Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL

cervical cancer screening trial. International Journal of Cancer, 144, 2587–2595. https://doi.org/10.1002/ijc.32083

Copley, K. E., & Shorter, J. (2023). Repetitive elements in aging and neurodegeneration. Trends in Genetics, 39, 381–400. https://doi.org/10.1016/j.tig.2023.03.003

Curry, S. J., Krist, A. H., Owens, D. K., et al. (2018). Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA, 320, 674–686. https://doi.org/10.1001/jama.2018.10897

Curty, G., Marston, J. L., de Mulder Rougvie, M., et al. (2020). Human endogenous retrovirus K in cancer: A potential biomarker and immunotherapeutic target. Viruses, 12, 726. https://doi.org/10.3390/v12100726

Curty, G., Menezes, A. N., Brant, A. C., et al. (2021). Expression of retroelements in cervical cancer and their interplay with HPV infection and host gene expression. Cancers, 13, 3513. https://doi.org/10.3390/cancers13143513

De Felice, F., Marchetti, C., Palaia, I., et al. (2018). Immune check-point in cervical cancer. Critical Reviews in Oncology/Hematology, 129, 40–43. https://doi.org/10.1016/j.critrevonc.2018.04.003

De Sanjosé, S., Brotons, M., Pavón, M. A. (2018). The natural history of human papillomavirus infection. Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 2–13. https://doi.org/10.1016/j.bpobgyn.2017.12.009

Dhillon, P., Mulholland, K. A., Hu, H., et al. (2023). Increased levels of endogenous retroviruses trigger fibroinflammation and play a role in kidney disease development. Nature Communications, 14, 559. https://doi.org/10.1038/s41467-023-36197-4

Dong, B., Zou, H., Mao, X., et al. (2021). Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: A retrospective population-based cohort study. Therapeutic Advances in Medical Oncology, 13, 17588359211010939. https://doi.org/10.1177/17588359211010939

European Centre for Disease Prevention and Control. (2023). Antimicrobial resistance surveillance in Europe. ECDC.

Fontham, E. T. H., Wolf, A. M. D., Church, T. R., et al. (2020). Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 70, 321–346. https://doi.org/10.3322/caac.21628

Frazer, I. H. (2019). The HPV vaccine story. ACS Pharmacology & Translational Science, 2, 210–212. https://doi.org/10.1021/acsptsci.9b00060

Gavinski, K., & DiNardo, D. (2023). Cervical cancer screening. Medical Clinics of North America, 107, 259–269. https://doi.org/10.1016/j.mcna.2022.09.001

GBD 2023 Antimicrobial Resistance Collaborators. (2024). Global burden of bacterial antimicrobial resistance, 2010-2023. The Lancet, 403(10442), 187-212.

Giorgi Rossi, P., Carozzi, F., Ronco, G., et al. (2021). P16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. Journal of the National Cancer Institute, 113, 292–300. https://doi.org/10.1093/jnci/djaa157

Grunwitz, C., Salomon, N., Vascotto, F., et al. (2019). HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology, 8, e1629259. https://doi.org/10.1080/2162402X.2019.1629259

Guo, C. (2023). Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: Integrating single-cell RNA-sequencing and spatial transcriptome. Clinical and Translational Medicine, 13, e1219. https://doi.org/10.1002/ctm2.1219

Hoppe-Seyler, K., Bossler, F., Braun, J. A., et al. (2018). The HPV E6/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets. Trends in Microbiology, 26, 158–168. https://doi.org/10.1016/j.tim.2017.09.001

Jeronimo, J., Castle, P. E., Temin, S., et al. (2017). Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. Journal of Global Oncology, 3, 635–657. https://doi.org/10.1200/JGO.2017.008337

Johnson, W. E. (2019). Origins and evolutionary consequences of ancient endogenous retroviruses. Nature Reviews Microbiology, 17(6), 355–370. https://doi.org/10.1038/s41579-019-0205-5

Jönsson, M. E., Garza, R., Johansson, P. A., et al. (2020). Transposable elements: a common feature of neurodevelopmental and neurodegenerative disorders. Trends in Genetics, 36(8), 610–623. https://doi.org/10.1016/j.tig.2020.05.001

Ko, E. J., Song, K. S., Ock, M. S., et al. (2021). Expression profiles of human endogenous retrovirus (HERV)-K and HERV-R Env proteins in various cancers. BMB Reports, 54(5), 368–373. https://doi.org/10.5483/BMBRep.2021.54.5.046

Koensgen, D., Sehouli, J., Belau, A., et al. (2017). Clinical outcome of neoadjuvant radiochemotherapy in locally advanced cervical cancer: results of an open prospective, multicenter phase 2 study of the North-Eastern German Society of Gynecological Oncology. International Journal of Gynecological Cancer, 27(3), 500–506. https://doi.org/10.1097/IGC.0000000000000940

Koliopoulos, G., Nyaga, V. N., Santesso, N., et al. (2017). Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews, 8, CD008587. https://doi.org/10.1002/14651858.CD008587.pub3

Koster, S., Gurumurthy, R. K., Kumar, N., et al. (2022). Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming. Nature Communications, 13, 1030. https://doi.org/10.1038/s41467-022-28668-2

Kremer, W. W., Van Zummeren, M., Novianti, P. W., et al. (2018). Detection of hypermethylated genes as markers for cervical screening in women living with HIV. Journal of the International AIDS Society, 21(e25165). https://doi.org/10.1002/jia2.25165

Kyrgiou, M., Arbyn, M., Bergeron, C., et al. (2020). Cervical screening: ESGO–EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 123, 510–517. https://doi.org/10.1038/s41416-020-0956-7

Lei, J., Ploner, A., Elfström, K. M., et al. (2020). HPV vaccination and the risk of invasive cervical cancer. New England Journal of Medicine, 383, 1340–1348. https://doi.org/10.1056/NEJMoa1917338

Leon, K. E., Tangudu, N. K., Aird, K. M., et al. (2021). Loss of p16: a bouncer of the immunological surveillance? Life, 11(4), 309. https://doi.org/10.3390/life11040309

Li, C., Hua, K. (2022). Dissecting the single-cell transcriptome network of immune environment underlying cervical premalignant lesion, cervical cancer and metastatic lymph nodes. Frontiers in Immunology, 13, 897366. https://doi.org/10.3389/fimmu.2022.897366

Li, C., Ke, J., Liu, J., et al. (2020). DNA methylation data-based molecular subtype classification related to the prognosis of patients with cervical cancer. Journal of Cellular Biochemistry, 121(6), 2713–2724. https://doi.org/10.1002/jcb.29591

Li, M., Radvanyi, L., Yin, B., et al. (2017). Downregulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. Clinical Cancer Research, 23(19), 5892–5911. https://doi.org/10.1158/1078-0432.CCR-16-2473

Liu, C., Li, X., Huang, Q., et al. (2023). Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduction and Targeted Therapy, 8, 44. https://doi.org/10.1038/s41392-023-01300-0

Liu, C., Lu, J., Tian, H., et al. (2017). Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Molecular Medicine Reports, 15(3), 1063–1070. https://doi.org/10.3892/mmr.2016.6032

Liu, H., Xu, J., Yang, Y., et al. (2021). Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1. Proceedings of the National Academy of Sciences, 118(26), e2014195118. https://doi.org/10.1073/pnas.2014195118

Mayadev, J., Nunes, A. T., Li, M., et al. (2020). CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. International Journal of Gynecological Cancer, 30(8), 1065–1070. https://doi.org/10.1136/ijgc-2020-001524

Mayadev, J., Zamarin, D., Deng, W., et al. (2020). Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. International Journal of Gynecological Cancer, 30(5), 701–710. https://doi.org/10.1136/ijgc-2020-001491

McBride, A. A. (2017). Mechanisms and strategies of papillomavirus replication. Biological Chemistry, 398(10), 919–927. https://doi.org/10.1515/hsz-2017-0131

Melnikow, J., Henderson, J. T., Burda, B. U., et al. (2018). Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320(7), 687–705. https://doi.org/10.1001/jama.2018.10780

Mileshkin, L. R., Moore, K. N., Barnes, E. H., et al. (2023). Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncology, 24(4), 468–482. https://doi.org/10.1016/S1470-2045(23)00003-5

Mix, J. M., Van Dyne, E. A., Saraiya, M., et al. (2021). Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15–29 years in the United States, 1999–2017: an ecologic study. Cancer Epidemiology, Biomarkers & Prevention, 30(1), 30–37. https://doi.org/10.1158/1055-9965.EPI-20-0976

Murray, C. J. L., et al. (2024). Global disease burden estimates for infectious diseases 1990-2023. The Lancet, 403(10441), 1-38.

Oliver, S. E., Unger, E. R., Lewis, R., et al. (2017). Prevalence of human papillomavirus among females after vaccine introduction—National Health and Nutrition Examination Survey, United States, 2003–2014. Journal of Infectious Diseases, 216(5), 594–603. https://doi.org/10.1093/infdis/jix364

Oyouni, A. A. A. (2023). Human papillomavirus in cancer: infection, disease transmission, and progress in vaccines. Journal of Infection and Public Health, 16(5), 626–631. https://doi.org/10.1016/j.jiph.2023.02.004

Pal, A., & Kundu, R. (2019). Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Frontiers in Microbiology, 10, 3116. https://doi.org/10.3389/fmicb.2019.03116

Panda, A., de Cubas, A. A., Stein, M., et al. (2018). Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight, 3(19), e121522. https://doi.org/10.1172/jci.insight.121522

Pardini, B., De Maria, D., Francavilla, A., et al. (2018). MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer, 18, 696. https://doi.org/10.1186/s12885-018-4600-3

Pei, J., Shu, T., Wu, C. Y., et al. (2023). Impact of human papillomavirus vaccine on cervical cancer epidemic: evidence from the surveillance, epidemiology, and end results program. Frontiers in Public Health, 10, 998174. https://doi.org/10.3389/fpubh.2022.998174

Perkins, R. B., Wentzensen, N., Guido, R. S., et al. (2023). Cervical cancer screening. JAMA, 330(6), 547–558. https://doi.org/10.1001/jama.2023.12264

Piña-Sánchez, P. (2022). Human papillomavirus: challenges and opportunities for the control of cervical cancer. Archives of Medical Research, 53(6), 753–769. https://doi.org/10.1016/j.arcmed.2022.09.001

Prudden, H. J., Achilles, S. L., Schocken, C., et al. (2022). Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021–March 2022. Vaccine, 40(41), 5843–5855. https://doi.org/10.1016/j.vaccine.2022.07.038

Qiu, H., Cao, S., & Xu, R. (2021). Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Communications, 41(10), 1037–1048. https://doi.org/10.1002/cac2.12197

Rahangdale, L., Mungo, C., O'Connor, S., et al. (2022). Human papillomavirus vaccination and cervical cancer risk. BMJ, 379, e070115. https://doi.org/10.1136/bmj-2022-070115

Ramos da Silva, J., Bitencourt Rodrigues, K., Formoso Pelegrin, G., et al. (2023). Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Science Translational Medicine, 15, eabn3464. https://doi.org/10.1126/scitranslmed.abn3464

Rezaei, S. D., Hayward, J. A., Norden, S., et al. (2021). HERV-K gag RNA and protein levels are elevated in malignant regions of the prostate in males with prostate cancer. Viruses, 13(3), 449. https://doi.org/10.3390/v13030449

Soleimani-Jelodar, R., Arashkia, A., Shoja, Z., et al. (2024). The expression analysis of human endogenous retrovirus-K env, Np9, and rec transcripts in cervical cancer. Journal of Medical Virology, 96(1), e29501. https://doi.org/10.1002/jmv.29501

Stricker, E., Peckham-Gregory, E. C., Scheurer, M. E., et al. (2023). CancerHERVdb: human endogenous retrovirus (HERV) expression database for human cancer accelerates studies of the retrovirome and predictions for HERV-based therapies. Journal of Virology, 97(5), e0005923. https://doi.org/10.1128/jvi.00059-23

Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Tavakolian, S., Goudarzi, H., Moridi, A., et al. (2021). Analysing the HERV-K env, np9, rec and gag expression in cervical tissues. New Microbes and New Infections, 44, 100936. https://doi.org/10.1016/j.nmni.2021.100936

The Cancer Genome Atlas Research Network. (2017). Integrated genomic and molecular characterization of cervical cancer. Nature, 543(7645), 378–384. https://doi.org/10.1038/nature21386

Tiiti, T. A., Selabe, S. G., Bogers, J., et al. (2022). High prevalence of and factors associated with human papillomavirus infection among women attending a tertiary hospital in Gauteng Province, South Africa. BMC Cancer, 22, 854. https://doi.org/10.1186/s12885-022-09971-8

Tse, S. W., McKinney, K., Walker, W., et al. (2021). mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. Molecular Therapy, 29(7), 2227–2238. https://doi.org/10.1016/j.ymthe.2021.04.021

Tsu, V. D., LaMontagne, D. S., Atuhebwe, P., et al. (2021). National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Preventive Medicine, 144, 106335. https://doi.org/10.1016/j.ypmed.2020.106335

Wang, J., Li, Z., Gao, A., et al. (2019). The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomedicine & Pharmacotherapy, 120, 109444. https://doi.org/10.1016/j.biopha.2019.109444

World Bank. (2022). The global economic burden of antimicrobial resistance. World Bank Publications.

World Health Organization. (2023). Global report on infection prevention and control. WHO Press.

World Health Organization. (2024). Antimicrobial resistance global surveillance report. WHO Press.

Wu, Q., Zhao, X., Fu, Y., et al. (2017). A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. Cancer Medicine, 6(5), 1091–1101. https://doi.org/10.1002/cam4.1080

Yadav, C., Yadav, R., Chabbra, R., et al. (2023). Overview of genetic and epigenetic regulation of human papillomavirus and apoptosis in cervical cancer. Apoptosis, 28(8), 683–701. https://doi.org/10.1007/s10495-023-01845-9

Yu, C., Lei, X., Chen, F., et al. (2022). ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nature Communications, 13, 3501. https://doi.org/10.1038/s41467-022-31234-2

Yue, S., Wang, Q., Zhang, J., et al. (2023). Understanding cervical cancer at single-cell resolution. Cancer Letters, 576, 216408. https://doi.org/10.1016/j.canlet.2023.216408

Zheng, Y., Li, X., Jiao, Y., et al. (2022). High-risk human papillomavirus oncogenic E6/E7 mRNAs splicing regulation. Frontiers in Cellular and Infection Microbiology, 12, 929666. https://doi.org/10.3389/fcimb.2022.929666

Zhou, L., Qiu, Q., Zhou, Q., et al. (2022). Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer. Nature Communications, 13, 2563. https://doi.org/10.1038/s41467-022-30275-1

Zou, Z., Fairley, C. K., Ong, J. J., et al. (2020). Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Global Health, 8(10), e1335–e1344. https://doi.org/10.1016/S2214-109X(20)30294-8

Zummeren, M. V., Kremer, W. W., Leeman, A., et al. (2018). HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. Modern Pathology, 31(11), 1842–1850. https://doi.org/10.1038/s41379-018-0105-8